<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04697316</url>
  </required_header>
  <id_info>
    <org_study_id>tDCS-ADHD</org_study_id>
    <nct_id>NCT04697316</nct_id>
  </id_info>
  <brief_title>Transcranial Direct Current Stimulation (tDCS) as a Cognitive Functioning Enhancement Treatment for ADHD Patients Compared to Healthy Controls</brief_title>
  <official_title>Transcranial Direct Current Stimulation (tDCS) as a Cognitive Functioning Enhancement Treatment for ADHD Patients Compared to Healthy Controls</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hebrew University of Jerusalem</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hebrew University of Jerusalem</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the possible effects of tDCS (Transcranial Direct Current&#xD;
      Stimulation) treatment to the left DLPFC on cognitive functions which were found to be&#xD;
      deficient amongst ADHD patients. The study will include 100 subjects, 50 of whom diagnosed&#xD;
      with ADHD. Subjects will complete the CAARS questionnaire to measure ADHD symptoms severity.&#xD;
      Next, subjects will complete a series of cognitive tasks, after which they will receive&#xD;
      either tDCS treatment or a sham treatment. Finally, subjects will repeat the cognitive tasks.&#xD;
      Later that day, a telephonic follow up will take place. ADHD symptoms will be assessed again&#xD;
      the next day.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2021</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>N-back</measure>
    <time_frame>through study completion, about six months</time_frame>
    <description>improved working memory: increase in Hit rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stroop</measure>
    <time_frame>through study completion, about six months</time_frame>
    <description>improved interference control: shorter RTs, increase in correct responses</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stop-signal</measure>
    <time_frame>through study completion, about six months</time_frame>
    <description>improved response inhibition: shorter RTs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time Reproduction task</measure>
    <time_frame>through study completion, about six months</time_frame>
    <description>improved time perception: increased accuracy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Continuous Performance Task</measure>
    <time_frame>through study completion, about six months</time_frame>
    <description>improved continuous concentration: shorter RT's, decrease in errors</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Navon task</measure>
    <time_frame>through study completion, about six months</time_frame>
    <description>improved accuracy, shorter RT's</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ADHD symptoms - CAARS questionnaire</measure>
    <time_frame>through study completion, about six months</time_frame>
    <description>decrease in symptoms severity</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Transcranial Direct Current Stimulation</condition>
  <arm_group>
    <arm_group_label>ADHD tDCS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ADHD Sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy control tDCS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy control Sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcranial Direct Current Stimulation</intervention_name>
    <description>To stimulate the left DLPFC, the anode electrode will be placed over F3 and the cathode will be placed over F4. Each stimulation will be applied for 20 min at 2mA intensity.</description>
    <arm_group_label>ADHD tDCS</arm_group_label>
    <arm_group_label>Healthy control tDCS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham</intervention_name>
    <description>For the sham treatment, stimulation will be stopped after 30 seconds. Current will be renewed five times throughout the session for 2 seconds each time, to mimic the tDCS stimulation.</description>
    <arm_group_label>ADHD Sham</arm_group_label>
    <arm_group_label>Healthy control Sham</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:Participation criteria for healthy participants&#xD;
&#xD;
          1. Right hand dominance.&#xD;
&#xD;
          2. No psychiatric nor neural diagnosis.&#xD;
&#xD;
          3. Participants must be able to comprehend the study's procedure and sign an informed&#xD;
             consent.&#xD;
&#xD;
        Participation criteria for ADHD diagnosed participants&#xD;
&#xD;
          1. ADHD diagnosis (according to DSM V).&#xD;
&#xD;
          2. Right hand dominance.&#xD;
&#xD;
          3. Participants must be able to comprehend the study's procedure and sign an informed&#xD;
             consent.&#xD;
&#xD;
          4. Participants who regularly use Methylphenidate will be required to avoid the&#xD;
             medication for 24 hours prior to study and 12 hours post study.&#xD;
&#xD;
             -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  a. Other psychiatric diagnoses (additional to ADHD). b. Drug use (excluding&#xD;
             Methylphenidate). c. Neurological disorders. d. Pacemaker, Insulin pump&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Noa Beiman</last_name>
    <phone>972506998194</phone>
    <email>noa.beiman@mail.huji.ac.il</email>
  </overall_contact>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 31, 2020</study_first_submitted>
  <study_first_submitted_qc>January 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 6, 2021</study_first_posted>
  <last_update_submitted>January 5, 2021</last_update_submitted>
  <last_update_submitted_qc>January 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hebrew University of Jerusalem</investigator_affiliation>
    <investigator_full_name>Noa Beiman</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

